Developing and validating a survival prediction model for NSCLC patients through distributed learning across three countries

Abstract Purpose Tools for survival prediction for non-small cell lung cancer (NSCLC) patients treated with (chemo)radiotherapy are of limited quality. In this work, we develop a predictive model of survival at two years. The model is based on a large volume of historical patient data and serves as a proof of concept to demonstrate the distributed learning approach. Patients and methods Clinical data from 698 lung cancer patients, treated with curative intent with chemoradiation (CRT) or radiotherapy (RT) alone were collected and stored in 2 different cancer institutes (559 patients at Institute 1 (Country 1)), 139 at University of Institute 2 (Country 2). The model was further validated on 196 patients originating from the Institute 3 (Institute 3, Country 3). A Bayesian network model was adapted for distributed learning (watch the animation: link censored). Two-year post-treatment survival was chosen as endpoint. The Institute 1 cohort data is publicly available at (link censored) and the developed models can be found at (link censored). Results Variables included in the final model were T and N stage, age, performance status, and total tumor dose. The model has an AUC of 0.66 on the external validation set and an AUC of 0.62 on a 5-fold cross-validation. A model based on T and N stage performed with an AUC of 0.47 on the validation set, significantly worse than our model (P